
Vittoria Biotherapeutics to Present Phase 1 Results for Senza5 CART5 in T-Cell
Phase 1 VIPER-101 abstract reports 88% overall response rate and 75% complete response rate with durable CD5-negative T-cell reconstitutionSenza5 CART5 holds FDA RMAT and Orphan Drug designations; the Company plans…
Read report ↗









